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Abstract 
Mushrooms have the ability to promote apoptosis in tumor cell lines, but the mechanism of 
action is not quite well understood. Inhibition of the interaction between Bcl-2 and pro-
apoptotic proteins could be an important step that leads to apoptosis. Therefore, the discovery 
of compounds with the ability to inhibit Bcl-2 is an ongoing research topic in drug discovery. 
In this study, we started by analyzing Bcl-2 experimental structures that are currently 
available in Protein Data Bank database. After analysis of the more relevant Bcl-2 structures, 
4 were finally selected. An analysis of the best docking methodology was then performed 
using a cross-docking and re-docking approach while testing 2 docking softwares: AutoDock 
4 and AutoDock Vina. Autodock4 provided the best docking results and was selected to 
perform a virtual screening study applied to a dataset of 40 Low Molecular Weight (LMW) 
compounds present in mushrooms, using the selected Bcl-2 structures as target. Results 
suggest that steroid are the more promising family, among the analyzed compounds, and may 
have the ability to interact with Bcl-2 and this way promoting tumor apoptosis. The steroids 
that presented lowest estimated binding energy (∆G) were: Ganodermanondiol, Cerevisterol, 
Ganoderic Acid X and Lucidenic Lactone; with estimated ∆G values between -8,45 and -8,23 
Kcal/mol. A detailed analysis of the docked conformation of these 4 top ranked LMW 
compounds was also performed and illustrates a plausible interaction between the 4 top raked 
steroids and Bcl-2, thus substantiating the accuracy of the predicted docked poses. Therefore, 
tumoral apoptosis promoted by mushroom might be related to Bcl-2 inhibition mediated by 
steroid family of compounds. 
  
 
 
Sumário 
Os cogumelos apresentam a capacidade de promover a apoptose em linhas células tumorais, 
No entanto o seu mecanismo de ação não é completamente conhecido. A inibição da interação 
entre Bcl-2 e proteínas pro-apoptóticas pode ser um passo importante na iniciação do processo 
de apoptose tumoral. Por essa razão, a descoberta de compostos que inibam a proteína Bcl-2 é 
uma área importante na descoberta de novos fármacos antitumorais. Neste estudo, começou-
se por analisar as estruturas experimentais de Bcl-2 atualmente presentes na base de estruturas 
Protein Data Bank. Após análise das estruturas de Bcl-2 mais relevantes, 4 foram escolhidas. 
Um estudo de “cross-docking” e “re-docking” foi então realizado para escolher a metodologia 
de “docking” mais adequada. Testaram-se 2 softwares, o AutoDock 4 e o AutoDock Vina, e 
verificou-se que o AutoDock 4 apresentava melhores resultados, tendo sido o selecionado 
para realizar os ensaios de “screening” virtual dos 40 compostos de baixo peso molecular 
presentes em cogumelos, utilizando as 4 estruturas selecionadas. Os resultados obtidos 
sugerem que os esteroides são a família de compostos mais prometedores de entre as famílias 
de compostos estudadas. Os esteroides que apresentaram valores de energia de ligação (∆G) 
mais baixos foram: Ganodermanondiol, Cerevisterol, Ácido Ganoderico X and Lactona 
Lucidénica, com valores de ∆G estimado entre -8,45 e -8,23 Kcal/mol. Uma análise detalhada 
da conformação de ligação foi também realizada dos 4 melhores compostos de baixo peso 
molecular melhor classificados. Esta análise demonstra um modo de interação plausível entre 
os compostos e a estrutura da Bcl-2, consubstanciando a eficácia dos resultados obtidos por 
“docking”. Conclui-se que o processo inibição de apoptose tumoral observada em cogumelos 
pode estar relacionado com a inibição da Bcl-2 por esteroides presentes nos cogumelos.  
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1. INTRODUCTION 
 
1.1. Mushrooms as potential source of bioactive compounds 
For centuries mushrooms have been used as human food and have been appreciated for 
texture and flavours as well as for medicinal purposes. However, the use of mushrooms as an 
important source of biological active substances with medicinal value has only recently been 
worthy of note. Several bioactivities of mushrooms have been studied including antibacterial, 
antitumor, antioxidant, antifungal, antiviral and anti-inflammatory, to name a few (Chang & 
Miles, 2004; Daba & Ezeronye, 2003). In the present work we will focus on antitumor 
activity of mushrooms, especially as a potential source of compounds with antitumor activity. 
Mushrooms components vary in their chemical nature and include High Molecular Weight 
(HMW) and Low Molecular Weight (LMW) compounds. Both types of compounds may be 
involved in the antitumor activity of mushrooms. In this work, because we are studying the 
potential of mushrooms compounds as inhibitors of the Bcl-2 protein target, we will focus on 
LMW compounds present in mushrooms, although HMW compounds will also be referred 
(Ferreira et al., 2010). 
 
1.1.1. High Molecular Weight (HMW) compounds present in mushrooms 
HMW mushrooms compounds with antitumor potential are structurally characterized as 
having long-chains, and include homo and hetero polysaccharides, glycoproteins, 
glycopeptides, proteins and RNA-protein complexes (Ferreira et al., 2010; Patel & Goyal., 
2012).  
Several phytochemicals have been isolated from medicinal mushrooms and three of those, 
which are carcinostatic polysaccharide drugs, have been developed from mushrooms in Japan. 
These are “Krestin” (PSK), from the cultured mycelium of Kawaratake (Trametes versicolor), 
“Lentinan” from the fruiting bodies of Shiitake (Lentinus edodes) and “Schizophyllan” 
(Sonifilan) from the culture fluid of Suehirotake (Schizophyllum commune). Lentinan and 
schizophyllan are pure-glucans, whereas PSK is a protein bound polysaccharide. The 
biological activity of these three products is related to their immunomodulating properties, 
which enhance the host’s defense against various forms of infectious disease (Zaidman et al., 
2005). 
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More recent studies have shown other mushrooms HMW compounds with antitumor activity. 
For example proteoglycan, a heavily glycosylated protein purified from Phellinux linteus, has 
shown anti-proliferative effect on human hepatocellular liver carcinoma (HepG2), human 
colon adenocarcinoma (HT-29), human lung cancer (NCIH 460) and human breast 
adenocarcinoma (MCF-7) cell lines. In vitro anti-proliferative activities of water-soluble 
polysaccharides extracted from the fruiting body and mycelium of Pleurotus tuber regium 
have also been discovered. Also, the isolation of lectin, a homodimeric 32.4 kDa glycoprotein 
with specific binding sites for sugars, isolated from fresh fruiting bodies of Pleurotus 
citrinopileatus have been shown to cause 80% inhibition of tumor growth (Ferreira et al., 
2010; Patel & Goyal, 2012). 
 
1.1.2. Low Molecular Weight (LMW) compounds present in mushrooms 
LMW compounds present in mushrooms with known antitumor potential are usually 
secondary metabolites and include: quinones and hydroquinones, isoflavones, catechols, 
amines and amides, sesquiterpenes and steroids. The current knowledge of mushrooms LMW 
compounds with some type of antitumor activity have been reviewed by Ferreira et al., 2010, 
and are presented in Table 1, with the respective chemical representation of the compounds 
presented in Figure 1. Although there are most likely a large number of mushroom LMW 
compounds with antitumor activity yet to be discovered, the list of 40 LMW compounds is a 
very good starting point, and will be our mushroom LMW compound dataset to be analyzed 
in this study, as potential Bcl-2 inhibitors (Froufe et al., 2012). 
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Figure 1. Chemical structure of the LMW compounds with anti-cancer potential isolated from mushrooms. 
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The known antitumor activity of the 40 LMW compound dataset will now be briefly 
overviewed. The LMW dataset includes 3 macrolidic fungal metabolites produced by 
Clitocybe clavipes: clavilactones A (CA), clavilactones B (CB), and clavilactones D (CD). 
These compounds were identified as inhibitors of protein tyrosine kinases. Also our LMW 
database include 2 epoxy compounds; panepoxydone (isolated from Panus conchatus, Panus 
rudis, and from Lentinus crinitus) and cycloepoxydon (isolated from a Xylaria strain); that are 
known to inhibit NF-κB, a transcription factor that is activated in cancer disease. 
The isoflavonoid genistein have been shown to inhibit proliferation of breast cancer and 
prostate cancer cells. Genistein have been shown to act by inhibition of protein tyrosine 
kinase activity, regulating the proliferation of cancer cells and consequently inhibiting Cdc2 
kinase.  
The gerronemins A-F extracts of a Gerronema species showed Cyclo-Oxygenase 2 enzyme 
inhibition and 2-Aminophenoxazin-3-one (Questiomycin A). Belonging to amines and amides 
family of compounds, they have shown antitumor potential as a non-steroid aromatase 
inhibitor (Zaidman et al., 2005).   
The sesquiterpenes illudin S and illudin M, obtained from the mushrooms Omphalotus 
illudens and Lampteromyces japonicas, behave as alkylating agents of protein and DNA 
(Zaidman et al., 2005).   
Ganoderma lucidum contains a high amount of steroid compounds. Currently around 20 
different steroids have been isolated with therapeutic effects. Lucidenic acid O and Lucidenic 
lactone have shown DNA polymerase ɑ, ß inhibition activity, while Cerevisterol presented 
DNA polymerase ɑ inhibition.  
Also Lucidumol A, B and F, Ganodermondiol and Ganodermontriol presented anti-tumor 
activity against several tumor cell lines. Ganoderic acids A presented NF-KB and Activator 
Protein1 (AP-1) inhibition activity while Ganoderic acid F has been shown to prevent 
invasion of metastatic cells.  
Also Ganoderic acid W, X, Y, T presented DNA topoisomerase inhibition and anticancer 
activities (Patel & Goyal, 2012; Sliva, 2004).  
Finally steroid compounds extracted from Grifola frondosa: ergosterol, ergostra-4, 6, 8(14), 
22-tetraen-3-one; have shown Cyclo-Oxygenase enzyme inhibition (Zaidman et al., 2005). 
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Table 1. Mushrooms LMW compounds with anticancer bioactivity (adapted from Ferreira et al., 2010). 
 Compound familly Compound Anticancer bioactivity 
Quinones and 
hydroquinones 
Panedoxine (1a) 
NF-kB inhibitor 
Cycloepoxydol (1b) 
Clavilactones A (1c)  
Protein tyrosine kinases inhibitor 
 
Clavilactones B (1d) 
Clavilactones D (1e) 
490 Quinone (1f) DNA polymerase ɑ inhibitor 
Hydroquinone (1g) Matrix Metallo-Proteinase (MMPs) inhibitors 
Isoflavones 
Catechols 
 
 
 
 
 
 
 
Genistein (2a) Cdc2 kinase modulator 
Hispidin (3a) PKCß inhibitor 
Gerronemins A (3b) 
 
Cyclo-OXygenase-2 (COX-2) inhibitor 
 
Gerronemins B (3c) 
Gerronemins C (3d) 
Gerronemins D (3e) 
Gerronemins E (3f) 
Gerronemins F (3g) 
Amines and amides 
2-Aminophenoxazin-3-one (Questiomycin 
A) (4a) 
Aromatase inhibitor 
Putrescine-1,4-dicinnamide (4b) Apoptosis inducer 
Sesquiterpenes 
Illudin S (5a) DNA alkylating 
agent Illudin M (5b) 
Steroids 
 
 
 
 
 
 
5,6-Epoxy-24(R)-methylcholesta-7,22-dien-
3β-ol (6a) 
Sulfatase inhibitor 
Ergosterol (6b) 
Cyclooxygenase inhibitor 
Ergosta-4,6,8(14),22-tetraen-3-one (6c) 
Lucidenic acid O (6d) 
DNA polymerase ɑ, ß inhibitions 
Lucidenic lactone (6e) 
Cerevisterol (6f) DNA polymerase ɑ inhibition 
Lucidumol A (6g) 
Anticancer activity against some cell lines 
Lucidumol B (6h) 
Ganoderiol F (6i) 
Ganodermanondiol (6j)  
Ganodermanontriol (6k) 
Ganoderic acid A (6l) NF-KB and AP-1 inhibitor 
Ganoderic acid F (6m) prevention of invasion of metastatic cells 
Ganoderic acid W (6n) 
DNA topoisomerase inhibitor 
Ganoderic acid X (6o) 
Ganoderic acid Y (6p) 
Ganoderic acid T (6q) 
Polyporenic acid C (6r) MMPs inhibitor 
Dehydroebriconic acid (6s) DNA topoisomerase II inhibitor 
Fomitellic acid A (6t) DNA polymerase ɑ and ß 
inhibitors Fomitellic acid B (6u) 
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1.2. Bcl-2 as a potential protein target for drug discovery 
Protein-protein interactions (PPI) play an important role in signaling pathways that regulate 
biological processes in the cell (Dong et al., 2014). One of the biological processes that are 
tightly regulated is apoptosis and a large number of proteins, some known and some still 
unknown, are involved in this signaling pathway. Bcl-2 (B cell lymphoma-2) protein is the 
best studied of the proteins involved in the regulation of apoptosis and that is the reason why 
Bcl-2 protein also names the family of proteins that it belongs to. Several studies have shown 
that overexpression of Bcl-2 leads to cancer and numerous Bcl-2 inhibitors have been 
developed with antitumor activity (Kang & Reynolds., 2009). 
Understanding the PPI mechanisms of Bcl-2 with other proteins, also involved in the 
regulation of apoptosis, is thus of great interest for the discovery of potential new anticancer 
drugs. Still, the discovery of drugs that target Bcl-2 using Cheminformatic tools remains a 
major challenge.  
 
1.2.1. The Bcl-2 protein family and its role in apoptosis 
The Bcl-2 protein family is composed of important protein mediators of the apoptotic 
response. The proteins belonging to this family are structurally related and include pro-
apoptotic and anti-apoptotic proteins that interact with each other. The common feature that 
all Bcl-2 proteins share is the presence of a conserved short sequence of amino acids, known 
as Bcl-2 homology (BH) domain. The BH domain plays an important role in each Bcl-2 
family protein function. In addition, the C-terminal region of Bcl-2 proteins are dominated by 
the presence of hydrophobic residues, not well conserved, that are known as the 
transmembrane (TM) region, important for membrane attachment (Czabotar et al., 2014; 
Kvansakul & Hinds., 2015).  
The Bcl-2 family members are classified into 3 main functional groups (Figure 2):   
(1) anti-apoptotic or pro-survival proteins  
(2) pro-apoptotic effector proteins (pro-apoptotic effectors)  
(3) pro-apoptotic activator proteins (pro-apoptotic activators) 
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Figure 2: Apoptosis process and the interaction between proteins belonging to the 3 Bcl-2 families.  
Anti-Apoptotic Family: MCl-1 (Myeloid Cell Leukemia) ; Bcl (B Cell Lymphoma) B, Bcl-XL and Bcl-W. Pro-
Apoptotic Activator: PUMA (p53 upregulated modulator of apoptosis); BID (BH3 interacting-domain); BIM 
(Bcl-2-like protein); BAD (Bcl-2-associated death promoter); NOXA (Phorbol-12-myristate-13-acetate-induced 
protein. Pro-Apoptotic Effector: BAX (Bcl-2-Associated X Protein); BAK (Bcl-2 homologous antagonist/killer). 
 
Members of the 3 Bcl-2 families interact with each other and together help regulate the 
apoptotic process. The pro-apoptotic effectors are closely associated with the mitochondrial 
membrane and promote the formation of pores in the mitochondrial membrane, initiating the 
apoptotic program. The pro-apoptotic activators are important mediators in the cellular 
response to stresses such as DNA damage and act by stimulating pro-apoptotic effectors. The 
anti-apoptotic protein act by directly interacting and inhibiting the apoptotic promoting effects 
from both pro-apoptotic effectors and pro-apoptotic activators. The dynamic balance that 
occurs between Bcl-2 anti-apoptotic and Bcl-2 pro-apoptotic proteins helps determine 
whether the cell initiates apoptosis (Figure 2). 
The human anti-apoptotic proteins present multiple BH-domains that support the most 
conserved BH1 and BH2 domains, a BH4 domain and may also support BH3 domain and 
include: Bcl-2, Bcl-xL, Bcl-w, Mcl-1 (myeloid cell leukemia sequence 1), A1 and Bcl-B.   
Like the pro-survival proteins, the pro-apoptotic effectors also include multi BH-domains and 
with the mains members being: Bax (Bcl-2 associated X protein), Bak (Bcl-2 
antagonist/Killer) also support BH1 and BH3 domain and obligatory contain BH3 domain that 
define the apoptotic behavior. The pro-apoptotic activators contain only one BH3 domain and 
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include PUMA (p53 upregulated modulator of apoptosis); BID (BH3 interacting-domain); 
BIM (Bcl-2-like protein 11); BAD (Bcl-2-associated death promoter); NOXA (Phorbol-12-
myristate-13-acetate-induced protein 1) (Kvansakul & Hinds., 2015). (Figure 2) 
 
1.2.2. Bcl-2 as a potential protein target for drug discovery 
The overexpression of Bcl-2 is common in several human cancers including prostate, lung, 
gastric, renal, epithelial, non-Hodgkin’s lymphoma, acute and chronic leukemia cancer with 
chemotherapeutic resistance (Kirkin et al., 2004). Although the number of protein members of 
the 3 Bcl-2 families implies that the apoptosis regulation is a complex and tightly process, the 
overexpression of Bcl-2 family probably promotes the inhibition of pro-apoptotic proteins 
thus stopping apoptosis in tumoral cells. Overexpression of Bcl-2 protein is thus a brake for 
what would otherwise be a healthy process of tumoral apoptosis. Inhibition of the PPI 
between Bcl-2 and pro-apoptotic proteins is thus an important step that leads to apoptosis of 
tumoral cells. By inhibiting Bcl-2, the free pro-apoptotic effector proteins will then promote 
MOM permeabilization and consequent tumoral apoptosis (Kang & Reynolds., 2009). 
Therefore, the discovery of compound with the ability to inhibit Bcl-2 is an ongoing research 
topic. 
 
1.2.3. Current knowledge on known Bcl-2 inhibitors 
The disruption of PPIs between anti-apoptotic and pro-apoptotic Bcl-2 family protein has 
been successfully established as an anticancer therapy, with the development of small 
molecule inhibitors that have entered in clinic trial and act by directly targeting the 
hydrophobic groove of the Bcl-2 protein and potentially restoring apoptosis (Souers et al., 
2013; Walensky, 2006). 
The first compound identified that has shown inhibition against Bcl-2 was gossypol (AT-101, 
Ascenta), currently in Phase I/II clinical trials. Gossypol analog, apogossypol (Burnham 
Institute), is in preclinical development (Kang & Reynolds, 2009).   
Navitoclax (ABT-263) is an orally bioavailable compound with a high affinity for both Bcl-2 
and Bcl-xL and it’s currently in phase 2 of clinical trial and activating the intrinsic apoptotic 
pathway (Waldman et al., 2016).  
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Venetoclax (ABT-199), an inhibitor which specifically targets Bcl-2, shows similar target-
driven activity, is significantly more potent than navitoclax (Souers et al., 2013) (Figure 3). 
 
Figure 3. Synthetic inhibitors of Bcl-2 in clinical trials. a- Gossypol (AT-101); b- Navitoclax (ABT263); c- 
Venetoclax (ABT199). 
 
1.3. Molecular Docking in Drug Discovery 
The discovery of new drugs has been an increasingly more difficult proposition for the 
pharmaceutical industry. The costs of producing a new drug have been increasing each year 
and this is the driving source for developing new more cost efficient tools. The use of 
bioinformatic and chemoinformatic tools to aid the drug discovery process is now common in 
the pharmaceutical industry as well as in public institutions (Grinter & Zou., 2014). In this 
study we use the bioinformatics methodology called molecular docking (or just docking) 
(Froufe et al., 2011). 
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Molecular docking belongs to the Structure Based Drug Design (SBDD) methodologies, 
where experimental structure information of the protein target of interest is mandatory. 
Docking simulation can only be performed when 3D (Three Dimensional) proteins structures, 
obtained either by X-ray crystallography or Nuclear Magnetic Resonance (NMR) techniques, 
are available (Ferreira, L et al., 2015). 
 
1.3.1. Methods and challenges of molecular docking 
Trying to predict if a given compound interacts with a protein target of interest, using only 
bioinformatic tools, is not an easy task. The docking tools must find the optimum binding 
orientation for the compound in the active site of the protein. This means that it must predict 
the correct ligand conformation and orientation, usually term the POSE. In addition the in 
silico method must also try to calculate the relative affinity of the compound. This 
quantitative value is usually referred as the SCORE. Many docking methods and programs 
have been developed and tested as docking applications. Docking POSE accuracy is usually 
evaluated by the ability to reproduce the experimentally determined binding mode of a ligand.  
The best docking programs correctly dock around 70–80% of the docked ligands, when tested 
on large sets of protein–ligand complexes, although these percentages are highly dependent of 
protein structures available and the accuracy of a given software. It is widely accepted that 
different docking softwares, because they use different POSE search algorithms, performed 
better for different protein structures, so it is always a sound methodology to use and test 
more than one docking software in a drug discovery project (Verdonk et al., 2008).  
The docking SCORE accuracy is usually evaluated by predicting the binding energy (∆G) or 
the constant inhibition (Ki) values for a number of known inhibitors of the protein target 
studied, and comparing them to known experimental values. A good correlation between 
predicted and experimental values will demonstrate a good performance of a given docking 
software in predicting POSE and SCORE of other tested compounds (Grinter & Zou., 2014; 
Ferreira, L et al., 2015). 
Finding out the best POSE for each tested compound into the binding site of the protein 
structure, and evaluating and comparing the SCORES of each docked compound are thus the 
main object to determine the potential of the studied compounds as inhibitors of a given 
protein target of interest (Ferreira. L et al., 2015; Kroemer., 2007).  
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1.3.2. Molecular docking softwares: AutoDock 4 and AutoDock Vina 
There are a number of docking softwares, either commercial or free for academic use. Among 
the latter, two of the most used softwares are AutoDock 4 (AD4) and AutoDock Vina (Vina). 
As all docking softwares, and SBDD methodologies in general, the knowledge of the 3D 
experimental structures of the protein target of interest is essential. Both AD4 and Vina 
require the knolwledge of the 3D “search space” that must include the binding site of the 
target protein. 
AD4 is maintained by the Molecular Graphics Laboratory, Scripps Research Institute, La 
Jolla. AutoDock 4 uses a Lamarckian Genetic algorithm to get fast predictions of the POSE 
and the SCORE as free energy of binding. This type of algorithm simulates the genetic 
selection that occurs in nature. A number of conformations of the ligand are generated 
(population) and evaluated, and the ligand structure with the best binding energy are selected 
and used to generate the next population. This process is performed millions of times till 
eventually the docked pose of the ligand with the best SCORE and POSE is obtained. In order 
to search efficiently the selected 3D conformational space and to speed up the interaction 
energy calculation, AD4 prepare grid map for each possible atom in the ligand or protein 
structure (Morris et al., 2009). AD4 is one of the first softwares to be developed and is one of 
the more widely used as there is a large number of studies that use AD4 (Meng et al., 2011; 
Morris et al., 2009).  
Vina is another docking software that is free for academic use that is also maintained by the 
Molecular Graphics Laboratory on The Scripps Research Institute, La Jolla. Vina uses a 
different algorithm that calculates automatically, quickly and without generating three 
dimensional grid map, a binding energy (∆G). It´s a more recent docking software and is 
currently very popular because a docking simulation is easier to prepare and each docking run 
is much faster than AD4. (Abreu et al., 2012; Trott & Olson., 2010). 
AD4 and Vina use a specific PDBQT file format, which is an extension of the pdb file format. 
The pdbqt format can easily be opened by most molecular modeling softwares, including 
AutoDockTools (ADT) and Pymol, used in this work (Lill & Danielson., 2011; Trott & 
Olson., 2010).  
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1.3.3. Virtual screening using AutoDock 4 and AutoDock Vina 
The concept of virtual screening is to find and prioritize the potential active compounds from 
a virtual library of compounds in the context of a computer aided drug discovery project 
(Kumar et al., 2007). The virtual screening methodologies are usually classified in two 
categories: ligand-based virtual screening (LBVS) and structure-based virtual screening 
(SBVS). The availability of docking softwares that can screen millions of compounds in a 
short time, and that can successfully predict the suitable conformation of a compound into the 
binding site of a protein target, makes docking one of the most used SBVS methodologies for 
virtual screening projects (Kumar et al., 2007). 
Specifically in anti-cancer drug discovery, because there are always new 3D protein structures 
being determined, VS methodologies have been widely used. Many of the recently discovered 
potential inhibitors of relevant protein targets have, at least in part of the drug discovery 
project, used some type of VS tool, and in most cases molecular docking methodologies were 
used. The main advantage of using this VS tools are: the increase in speed to the process, the 
possibility of automation of the process and specially the decrease of the costs associated with 
the drug discovery process. 
In this work, a number of tools have been used to perform VS of the selected LMW 
mushroom dataset of compounds using AD4 and Vina as docking tools. These tools include 
AutoDockTools (ADT) and MOLA.  
ADT is a graphical user interface that is part of the MGLTools suite and was implemented by 
the Molecular Graphics Laboratory at the Scripps Research Institute. ADT performs the 
preparation of the grid with the appropriate parameters to be used for AD4 docking studies. It 
prepares the protein structures in PDBQT format, needed for using AD4 and Vina. (Morris et 
al., 2008).  
MOLA is a free software for VS using AD4 and Vina on computer clusters. It’s integrated in 
a customized Live-CD LINUX operating system and was developed in our group (Abreu et 
al., 2010). MOLA is able to prepare large datasets of compounds for screening and also 
automates the complete VS project in computer clusters, using either AD4 or Vina as docking 
tools. It is especially useful when large datasets of compounds are going to be screened as it 
would be impossible to perform each docking run manually. 
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1.4. Objectives 
In order to better understand the possible mechanism of action of mushrooms anti-cancer 
bioactivity at a molecular level, a dataset of 40 low molecular weight (LMW) compounds, 
present in mushrooms, will be virtually screened against Bcl-2 (B cell /lymphoma-2), a pro-
apoptotic proteins known to be involved in several cancer situations.   
In this study, the LMW dataset of compounds will be virtually screened using two docking 
software tools: AutoDock 4 and AutoDock Vina. The validation of the selected Bcl-2 
experimental structures as targets, will be performed using a re-docking and cross-docking 
approach. The docking studies of the LMW dataset of compounds will then be performed 
using the selected Bcl-2 structures as targets. Compounds with the lowest predicted binding 
energy (pred∆G) are expected to be the more potent Bcl-2 inhibitors.  
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2. MATERIALS AND METHODS  
 
2.1. Ligand structures preparation (LMW compound dataset) 
The majority of the 40 LMW compound structures (Figure 1) were sketched using 
MarvinSketch version.1.25 (www.chemaxon.com), and saved in sdf file format. When 
available, some structures were downloaded, in sdf file format, from the PubChem compound 
database, belonging to the National Center for Biotechnology Information. Compound 
structures were then verified from the original articles (Wang Y et al., 2010).  
The chemical structures in sdf file format were then converted into pdb file format, using 
PyMol, an open-source structure visualization software. Next, AutoDockTools 1.5.2 (ADT) 
was used to perform the following procedures on each ligand structure: merge nonpolar 
hydrogen, add Gasteiger charges, set up rotatable bonds and  convert the ligands into pdbqt 
file format, adequate for AutoDock4 (AD4) and AutoDock Vina (Vina) use (Gasteiger et al., 
2005). 
 
2.2. Protein structure preparation 
The Bcl-2 experimental structures were all downloaded from the PDB database (Protein 
DataBank) (http://www.rcsb.org), with their respective PDB id’s code being: 4IEH, 4AQ3, 
4LVT and 4LXD. These Bcl-2 protein structures were experimentally determined using X-
Ray diffraction methods, and made available in PDB for all researches to use. For docking 
studies, the inhibitors of each protein structure were separated by removing the coordinates of 
the respective atoms from the pdb file. The water molecules atom coordinates, include in the 
co-crystallized protein structure, were also removed. When there was more than one protein 
chain represented in the pdb file, chain A was selected for docking. ADT software was then 
used to prepare the input files necessary for AD4 and Vina, by performing the following 
procedures: assignment of polar hydrogens, calculation of Gasteiger charges to the protein 
structures and conversion of the protein structures from pdb file format into pdbqt file format 
(Morris et al., 2009).   
 
 
 
15 
 
2.3. Virtual screening using molecular docking  
The docking studies were performed using two molecular docking softwares: AutoDock 4.2 
version (AD4) and AutoDock Vina (Vina) (Morris et al., 2009).  Both AD4 and Vina require 
the specification of the 3D “search space”, centered on the interaction site of the protein 
structure (Trott O. et al., 2010).  
The size of the grid box for Vina was 22*22*22 Å, for the X, Y, Z dimensional coordinates, 
applied for each protein structure interaction site. The default setting for spacing was 1 Å, and 
exhaustiveness value used was 16. For each PDB structures, the center coordinate was 
obtained from the analysis of the co-crystallized inhibitors for each protein structure (Abreu et 
al., 2012).  
For AD4, ADT was used to create atom grid affinity maps, for each atom type present in each 
of the 4 protein structures, using AutoGrid4 algorithm. ADT prepared the grid maps with the 
following parameters: the number of grid points for the X, Y, Z dimensional coordinates were 
88*88*88, with 0.250 Å regular spaces within the grid space selected. AD4 resolution of the 
grid space resulted in 88*0.250 = 22 Å grid space, the same grid space used for Vina. All 
affinity grid maps were centered on the active site and coordinates were selected in order to 
encompass the complete active site for each protein structure (Goodsell et al., 2008). AD4 
used the Lamarckian genetic algorithm (Morris et al., 1998), to perform the Bcl-2/compounds 
molecular docking studies. Docking parameters selected for AD4 runs were as follows: 50 
docking runs, population size of 200, random starting position and conformation, translation 
step ranges of 2.0 Å, mutation rate of 0.02, crossover rate of 0.8, local search rate of 0.06, and 
2.5 million energy evaluations. The entire virtual screening experiment was performed on 
Core AMD 2.0 GHz computers using MOLA (Abreu et al., 2010), a custom designed 
software to perform virtual screening studies using AD4 and Vina (Abreu et al., 2010). 
Estimated constant inhibition (Ki) for all compounds were calculated as follows: Ki = exp 
((ΔG*1000)/(Rcal*TK)), where ΔG is the estimated binding energy, calculated by AD4 and 
Vina, Rcal is 1.98719 and TK is 298.15. (Trott O. et al., 2009).  All structural analysis and 
figures with structure representations were produced and analyzed using PyMOL software 
(Seelige et al., 2010). 
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3. RESULTS AND DISCUSSION 
3.1. Bcl-2 molecular docking protocol validation 
 
Before performing virtual screening of our mushroom LMW dataset of compounds against 
Bcl-2 protein structures, a docking protocol or methodology must be selected and validated. 
Essentially this means that we must first select experimental 3D (three dimensional) structures 
of the protein target being studied; in this case Bcl-2, and then we must select suitable 
docking software to be used in the virtual screening study. 
Docking experiments are only possible if experimental structures of the protein target are 
available; preferably complexed with a known ligand or inhibitor. The selection of the 
experimental protein structures is an essential step of molecular docking studies as reliable 
docking results are highly dependent on the quality of the protein structures used. Once these 
protein structures are selected, the feasibility of using them can be evaluated by performing 
docking studies of the complexed ligands into the protein binding site and then analysing the 
docked conformation obtained. These docking studies are usually called re-docking and can 
be considered a control on the quality of the protein structure to be used for docking studies. 
If more than one experimental structure of the target with co-crystalized ligands is available, 
docking experiments can also be performed by using all ligands against all the selected 
protein structures. These docking studies are usually termed cross-docking. 
On this study we started by selecting adequate Bcl-2 crystal structures and then validating 
them by performing re-docking and cross-docking studies. Two docking softwares were used 
in this study: AutoDock 4 (AD4) and AutoDock Vina (Vina). Although both softwares were 
developed in the same laboratory, they use different approaches and algorithms. Each docking 
software may work better depending on the type of protein target and the objectives of the 
docking project. For this reason a decision was made to test both software’s on this re-
docking and cross-docking stage. 
 
3.1.1. Bcl-2 experimental structure selection 
 
A total of 13 human Bcl-2 experimentally obtained structures are currently available at the 
PDB protein structure database (Table 2). In order to maintain this work into a more 
manageable timeframe, due to computational constrains, it was decided to use a total of 4 Bcl-
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2 structures. First a decision was made to use only structures obtained by X-ray 
crystallography methodology. Structures obtained by Nuclear Magnetic Resonance (NMR) 
can also be used for docking studies but our group has more experience using X-ray 
structures. Also NMR structures were determined a long time ago and as a rule newer 
structures are preferred as in principle they have better resolution. From the 13 initial 
structures 7 presented X-ray determined structures. 
Table 2. Experimental structures of Bcl-2 available on Protein DataBank (PDB). 
PDB 
Code 
Method 
Resolution 
(Å) 
Co-crystallized 
LMW Inhibitor 
Experimental 
Ki value 
Reference 
5AGW X-ray 2,69 No No Smith et al. 2015 
5AGX X-ray 2,24 No No Smith et al. 2015 
4MAN X-ray 2,07 Yes No Park et al. 2013 
4LVT X-ray 2,05 Yes 0,044 nM Park et al. 2013 
4LXD X-ray 1,90 Yes 59 nM Park et al. 2013 
4IEH X-ray 2,10 Yes 14 nM Xie et al. 2013 
4AQ3 X-ray 2,40 Yes 37 nM Bertrand et al. 2012 
2O21 NMR N. A. Yes No Bruncko et al. 2007 
2O22 NMR N. A. Yes 67 nM Bruncko et al. 2007 
2O2F NMR N. A. Yes No Bruncko et al. 2007 
1YWN NMR N. A. Yes 30 nM Oltersdorf et al. 2005 
1GJH NMR N. A. No No Petros et al. 2001 
1G5M NMR N. A. No No Petros et al. 2001 
 
As this study evaluates the potential Bcl-2 inhibition activity of LMW compounds, only 
structures with co-crystallized LMW inhibitors were considered. From the 7 available Bcl-2 
structures, 5 presented LMW inhibitors.  
To reduce to 4 the number of Bcl-2 structures, only X-ray structures with experimental Ki 
(Inhibitory Constant) values were considered, with the following PDB structures: 4IEH, 
4AQ3, 4LVT and 4LXD (PDB entries) that are presented in bold on Table 2. The 4 PDB 
structures used present co-crystallized inhibitors from known families of Bcl-2 inhibitors: a 
heteroaryl-sulfonamide derivative in 4IEH, a phenylacyl-sulfonamide derivative in 4AQ3, and 
two benzamide derivative: Navitoclax drug in 4LVT and a Navitoclax analog in 4LXD 
(Figure 4). 
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Figure 4: Chemical representation of the co-crystalized ligands used for the docking control analysis. A: 4LVT, 
B: 4LXD, C: 4IEH, D: 4AQ3. 
 
3.1.2. Bcl-2 re-docking and cross-docking using AD4 and Vina 
 
In order to validate the docking approach for the Bcl-2 selected structures, the inhibitors were 
re-docked to the respective structure and then cross-docked to the other 4 selected structures. 
The docking scores obtained using both AD4 (Table 3) and Vina (Table 4) are present as 
estimated average binding energy (ΔG) and estimated inhibition constant (Ki) values. Tables 
3 and 4 also present the experimental Ki values obtained from the literature, and the 
difference between estimated and experimental Ki values are calculated as pKi difference 
(Estimated pKi – Experimental pKi), with pKi values calculated using the formula: pKi = - 
log10Ki. The ideal scenario will be that the pKi difference values were null. This would mean 
that the estimated inhibition scores obtained as estimated Ki values exactly matched the 
experimental Ki values. 
Comparing the results from AD4 and Vina, we can observe that the pKi differences are in 
general much smaller for AD4 compared to Vina. For AD4 the pKi difference values were: -
0,104; -0,058; -1,890 and -0,193; and for Vina; -0,341;-0,322; -3,741 and 0,138 for 4IEH, 
4AQ3, 4LVT and 4LXD inhibitors, respectively. For both AD4 and Vina, the higher pKi 
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difference was for Navitoclax (4LVT inhibitor). These results shows that both AD4 and Vina 
had difficulty in predicting the much higher potency of Navitoclax as a Bcl-2 inhibitor 
(experimental Ki value of 0,044 nM), when compared to the inhibitors of the other 3 
structures. Still the difference was much smaller for AD4. 
 
Table 3. AutoDock 4 re-docking and cross-docking results using the selected Bcl-2 crystal structures. 
*re-docking studies; **pKi= -log10Ki; ***pKi difference = (Estimated pKi – Experimental pKi) 
 
 
 
Figure 5. Correlation between experimental pKi and estimated pKi values, obtained using AD4, for the co-
crystallized inhibitors present in the 4 selected PDB structures (4IEH, 4AQ3, 4LVT and 4LXD).  
 
We then plotted the average experimental and estimated pKi values for both AD4 and Vina 
and presented the graph in figure 5 and 6. We can observe that AD4 presented a much better 
correlation between estimated and experimental values with a correlation coefficient of 
R² = 0,9848 
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Compound 
Estimated ΔG (Kcal/mol) 
Estimated 
Ki (nM) 
Estimated 
pKi** 
Experi- 
mental 
Ki (nM) 
Experi-
mental 
pKi**  
pKi 
difference 
*** 4IEH 4AQ3 4LVT 4LXD Average 
Inhibitor 
(4IEH) 
-9,91* -10,96 -10,32 -11,10 -10,57 17,8 7,75 14,0 7,85 -0,104 
Inhibitor 
(4AQ3) 
-9,19 -10,73* -11,23 -9,72 -10,22 32,4 7,49 37,0 7,43 -0,058 
Inhibitor 
(4LVT) 
-9,13 -12,39 -13,13* -13,13 -11,55 3,4 8,47 0,044 10,34 -1,890 
Inhibitor 
(4LXD) 
-10,33 -8,46 -10,63 -11,08* -10,13 37,9 7,42 59,0 7,23 -0,193 
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0,9848. This means that the more potent inhibitor (with the lowest experimental Ki, hence the 
higher pKi) was predicted by AD4 to be the more potent Bcl-2 inhibitor. In fact, AD4 ranked 
correctly all inhibitors from the more potent Navitoclax (4LVT) to less potent Navitoclax 
analogue (4LXD). For Vina, the correlation coefficient was 0,7239 but the correlation was 
inverted. This means that the more potent inhibitor (with the lowest experimental Ki, hence 
the higher pKi) was predicted by Vina to be the least potent Bcl-2 inhibitor. The ligand that is 
mainly responsible for the difference of results between AD4 and Vina is again Navitoclax 
and the inability, speciality of Vina, to predict Navitoclax astounding inhibition potency (3 
orders of magnitude more potent than the other inhibitors used). 
Another aspect that should be taken into account, when comparing AD4 and Vina 
performance, is the time it takes to perform the docking simulations. Considering the 
parameters used, an AD4 docking run for each inhibitor against each protein structure takes 
on average 90 minutes, while for Vina the same docking run takes on average 15 minutes. 
This means that the cross-docking and re-docking runs for just the 4 inhibitors used took 
about 24 hours of processing time for AD4 and just 4 hours for Vina. Considering the 40 
compounds from our mushrooms LMW library, to be used in the next virtual screening step, 
using AD4 and Vina means a processing time of about 10 and 1,5 days, respectively. This 
essentially means that, if docking accuracy for both softwares is similar, Vina is usually the 
selected docking software due to the much lower computer processing time needed.  
Still, taking into account all results for both AD4 and Vina, the accuracy of the estimated 
values results point to AD4 performing much better than Vina, and for this reason AD4 was 
selected for the next virtual screening step. 
 
Table 4. Vina re-docking and cross-docking results using the selected Bcl-2 crystal structures. 
*re-docking studies; **pKi= -log10Ki; ***pKi difference = (Estimated pKi – Experimental pKi) 
 
Compound 
Estimated ΔG (Kcal/mol) 
Estimated 
Ki (nM) 
Estimated 
pKi** 
Experi- 
mental 
Ki (nM) 
Experi-
mental 
pKi** 
pKi 
difference 
*** 4IEH 4AQ3 4LVT 4LXD Average 
Inhibitor 
(4IEH) 
-10,00* -11,00 -9,70 -10,30 -10,25 30,7 7,51 14,0 7,85 -0,341 
Inhibitor 
(4AQ3) 
-9,20 -10,10* -10,10 -9,40 -9,70 77 7,11 37,0 7,43 -0,322 
Inhibitor 
(4LVT) 
-10,50 -7,60 -7,60* -10,40 -9,03 242 6,62 0,044 10,36 -3,741 
Inhibitor 
(4LXD) 
-10,60 -8,50 -10,60 -10,50* -10,05 43 7,37 59,0 7,23 0,138 
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Figure 6. Correlation between experimental pKi values and estimated pKi values, obtained using Vina, for the 
co-crystallized inhibitors present in the 4 selected PDB structures (4IEH, 4AQ3, 4LVT and 4LXD).  
 
 
3.1.3. Conformation analysis of Bcl-2 re-docking studies  
 
The 3D docked conformation, predicted by AD4 for each Bcl-2 inhibitor, was also 
structurally analysed. This docked conformation analysis is usually performed by aligning the 
experimental conformation of the inhibitor, present in the experimental structure used, with 
the docked conformation of the same inhibitor predicted by the docking software, in this case 
AD4. Ideally the better the alignment, the more confident we are that the docking approach 
used will provide predictions with good accuracy.  
This analysis was performed for each of the 4 Bcl-2 inhibitors used. The docked conformation 
of each ligand was aligned with the experimental conformation bounded to the respective 
structure (Figure 7).  This means that Figure 7 represents the re-docking results obtained using 
AD4.  
We can observe that in general the predicted docked conformation occupies the same binding 
space as the experimental conformation. This binding space of Bcl-2 structure is composed of 
several binding pockets that collectively are usually termed Bcl-2 binding cleft, and is the 3D 
space were Bcl-2 usually binds with the interaction partner of the same Bcl-2 protein family.  
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Figure 7. Alignment of experimental (wire representation, white color) and docked conformations (sticks and 
balls representation, cyan color), obtained using AD4 for: (A) Navitoclax analog present in 4LXD, (B) 
Navitoclax present in 4LVT, (C) phenylacyl-sulfonamide derivative present in 4AQ3 and (D) heteroalryl-
sulfonamide derivative present in 4IEH. Superimpositions obtained by aligning the three Bcl-2 structures using 
Pymol. 
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From the alignments we can observe that the main skeleton of the compounds occupies the 
same Bcl-2 interaction space and with the correct inhibitor orientation. Still some inhibitor 
docked conformations are better aligned with the experimental structures than others and, in 
Figure 7, the alignments are presented from better to worst. In figure 7A, we can observe the 
Navitoclax analogue present in 4LXD structure. The superimposition is near perfect, with all 
the heteroaryl ring structures and linker groups occupying the same pockets, except for the 
terminal heteroaryl group that was predicted to be positioned more to the inside of the Bcl-2 
structure, when compared to the experimental structure. The Navitoclax alignment is also 
very good and can be observed in Figure 7B. Again the terminal aryl group occupies a 
different pocket, in this case more to the exterior of the Bcl-2 structure and the other terminal 
heteroaryl group with a Fluorine atom being displaced outwards of the pocket instead of 
inwards. When looking at the other compounds we can observe that the experimental and 
predicted binding conformation are less aligned with more heteroaryl groups displaced from 
the experimental binding pockets, still the same 3D space is occupied for both predicted 
docked and experimental conformation. 
These results are quite encouraging as a perfect alignment is not expected for such large 
compounds and with such a large binding area on Bcl-2 structure surface. In general the 
bigger the compounds and the interaction area are, the more difficult it is for the docking 
software to correctly predict docked conformations, as more variables have to be taken into 
consideration including, more possible rotatable bonds in the compound structure, and more 
possible binding pockets on the protein structure. Also the interaction site of Bcl-2 is quite 
exposed to the solvent and, although AD4 takes (de)solvation displacement (water molecules 
displacement) into consideration when doing the docking algorithm calculations, there are too 
many structural variables that the software has to account for and that are simplified by AD4 
docking algorithm. 
At the end of this re-docking and cross-docking methodology selection step, AD4 software 
was finally selected for the next virtual screening step. Docking studies will be performed 
using the 4 Bcl-2 structures selected and the average scores obtained will be used. 
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3.2. Virtual screening of the LMW mushroom compound dataset 
Once the best docking approach was established, a virtual screening was performed using the 
40 LMW selected dataset of mushroom compounds as ligands, and the 4 selected Bcl-2 
structures as targets. AD4 docking runs were performed using exactly the same AD4 docking 
parameters as with the 4 inhibitors on the re-docking and cross-docking studies. The LMW 
compounds were ranked according to estimated ΔG and Ki values and the results are present 
in table 5. 
 
The compounds with best docking scores and affinity were: Ganodermondiol (6j), 
Cerevisterol (6f), Ganoderic acid X (6o) and Lucidenic lactone (6e) with estimated Ki values 
of 645, 667, 787 and 935 nM, respectively. All the top ranked compounds belong to the 
steroid family of mushroom compounds. In fact, all the steroids screened scored better than 
the other LMW compound families studied (Table 5). Taking a closer look at the steroid 
structures (Figure 1), we can observe that steroids present a large hydrophobic skeleton, with 
differences between steroids occurring in terms of the number and position of small 
hydrophilic groups, usually: hydroxyl (OH) carbonyl groups (C=O) or carboxyl (COOH) 
groups. Steroids are thus amphipathic compounds with both 
hydrophobic and hydrophilic regions. We can thus hypothesize that the hydrophobic steroids 
skeleton probably interacts with the hydrophobic inside pockets of the Bcl-2 interaction site, 
and the steroid hydrophilic groups probably interacts with more external hydrophilic residues 
present on the Bcl-2 structure. 
This docking analysis provides strong evidence that the steroid mechanism of inducing 
apoptosis in tumor cells may be by interacting with Bcl-2 protein, thus preventing Bcl-2 from 
forming complexes with the respective proapoptotic protein interaction partners, namely Bak, 
Bax, and Bim. The free pro-apoptotic effector proteins will then be able to promote MOM 
permeabilization and consequence tumoral apoptosis.  It is important to note that, as apoptosis 
is a complex cellular event, Bcl-2 is most probably just one of the LMW mushroom 
compounds protein targets for apoptosis promotion. In this study we highlight steroids as a 
possible new class of Bcl-2 inhibitions, but steroids, and other classes of compounds present 
in mushrooms, will probably target other potential apoptosis inducting targets. Bcl-2 
inhibition is just one of the events that will act synergistically with inhibition or activation of 
other protein targets to promote tumor apoptosis. 
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Table 5. Virtual Screening of the LMW mushroom compound database using AutoDock4.  
Compound 
Familly 
Compound Code 
Estimated 
Ki (nM) Rank 
4IEH 4AQ3 4LVT 4LXD Average 
Quinones and 
Hydroquinones 
Panepoxydone 1a -4,72 -4,65 -4,74 -5,14 -4,81 296760 39 
Cycloepoxydon 1b -4,78 -4,35 -4,95 -5,27 -4,84 284499 38 
Clavilactones A 1c -6,86 -7,27 -7,3 -8,17 -7,40 3765 18 
Clavilactones B 1d -6,22 -7,27 -7,3 -8,17 -7,24 4932 19 
Clavilactones D 1e -6,32 -7 -7,08 -7,78 -7,05 6854 22 
490 Quinone 1f -4,27 -4,29 -3,92 -4,51 -4,25 770113 40 
Hydroquinone 1g -5,35 -5,09 -5,15 -5,86 -5,36 117288 37 
Isoflavones Genistein 2a -6,44 -5,6 -5,7 -6,2 -5,99 41016 32 
Catechols 
Hispidin 3a -5,86 -5,44 -5,97 -5,67 -5,74 62547 34 
Gerronemins A 3b -6,38 -5,44 -5,76 -5,73 -5,83 53506 33 
Gerronemins B 3c -5,78 -6,47 -6,92 -5,88 -6,26 25677 30 
Gerronemins C 3d -6,65 -6,06 -6,65 -5,12 -6,12 32659 31 
Gerronemins D 3e -7,29 -6,32 -6,86 -6,24 -6,68 12745 25 
Gerronemins E 3f -6,86 -7,22 -7,03 -6,07 -6,80 10452 23 
Gerronemins F 3g -5,42 -6,93 -7,3 -5,95 -6,40 20359 29 
Amines and 
amides 
(Questiomycin A 4a -5,57 -4,98 -5,62 -6,68 -5,71 64968 35 
Putrescine-1,4-dicinnamide 4b -6,56 -6,55 -7,11 -6,68 -6,73 11763 24 
Sesquiterpenes 
Illudin S 5a -5,73 -5,66 -5,32 -6,07 -5,70 66916 36 
Illudin M 5b -6,53 -5,77 -6,96 -6,87 -6,53 16279 28 
Steroids 
EMCD 6a -8,56 -7,5 -8,6 -7,15 -7,95 1482 9 
Ergosterol 6b -7,88 -8,06 -7,93 -7,49 -7,84 1792 11 
Ergosta-4,6,8(14),22-tetraen-3-
one 
6c -8,96 -8,07 -8,01 -7,55 -8,15 1066 8 
Lucidenic acid O 6d -8,13 -7,6 -7,73 -7,63 -7,77 2008 13 
Lucidenic lactone 6e -8,65 -8,87 -7,76 -7,62 -8,23 935 4 
Cerevisterol 6f -8,9 -8,25 -8,73 -7,82 -8,43 667 2 
Lucidumol A 6g -8,12 -7,85 -8,09 -7,39 -7,86 1725 10 
Lucidumol B 6h -8,41 -7,92 -8,6 -7,92 -8,21 955 5 
Ganoderiol F 6i -8,46 -7,8 -8,64 -7,8 -8,18 1018 6 
Ganodermanondiol 6j -8,64 -8,26 -8,69 -8,19 -8,45 645 1 
Ganodermanontriol 6k -9,15 -6,05 -6,18 -4,86 -6,56 15541 27 
Ganoderic acid A 6l -7,06 -7,15 -7,25 -6,88 -7,09 6407 21 
Ganoderic acid F 6m -6,99 -7,44 -8,56 -6,84 -7,46 3417 17 
Ganoderic acid W 6n -7,26 -8,46 -8,76 -7.51 -8,16 1044 7 
Ganoderic acid X 6o -8,2 -8,5 -8,45 -8,16 -8,33 787 3 
Ganoderic acid Y 6p -7,59 -7,16 -8,5 -7.08 -7,75 2085 16 
Ganoderic acid T 6q -8,72 -8,38 -8,16 -5,76 -7,76 2068 15 
Polyporenic acid C 6r -7,74 -7,11 -8,45 -7.38 -7,77 2028 14 
Dehydroebriconic acid 6s -7,98 -7,63 -8,25 -7,42 -7,82 1853 12 
Fomitellic acid A 6t -6,65 -6,4 -6,6 -6,99 -6,66 13127 26 
Fomitellic acid B 6u -7,44 -6,81 -7,88 -6,63 -7,19 5366 20 
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Although this varies between protein drug targets, in the drug discovery process, the potency 
of the drug candidates are usually expected to present Ki values in the nanoMolar range, with 
100 nM begin a threshold value. Steroids that showed more potent estimated Bcl-2 inhibition, 
namely Ganodermondiol (6j), Cerevisterol (6f), Ganoderic acid X (6o), Lucidenic lactone 
(6e), presented estimated Ki in the hundreds of nanoMolar range (between 645 and 935 nM). 
This fact points to a probable situation where not one but several steroids maybe acting 
synergistically to inhibit Bcl-2 protein target. It´s important to highlight that the presented 
study is performed using only computational tools, and that the proposed Bcl-2 inhibition, 
mediated by steroids, will need future experimental verification. Still several studies points to 
the fact that steroids, and specifically steroids found in mushrooms, are in fact a family of 
compound involved in tumoral apoptosis.  For example research and clinical studies support 
the beneficial effect of Ganoderma lucidum mushroom species for reducing and preventing 
cancer risk. Ganoderma lucidum yields a series of triterpenoid and steroid compounds with 
significant cytotoxicity and anti-inflammatory bioactivity including ganodermanondiol and 
Ganoderic acid X (Than et al., 2013). Ganoderma lucidum mushroom with anti-tumor activity 
has been proved by several experimental studies in cancer therapy (Yue et al., 2009). The 
steroid apoptosis induction is also supported by several reports stating that steroids induce 
apoptosis in several tumor cells (Choi et al., 2011; Harhaji et al., 2009). 
The top ranked steroids estimated to be the more potent Bcl-2 inhibitors: (Ganodermanondiol, 
Cerevisterol, Ganoderic acid X, Lucidenic lactone) are all steroids from the triterpenoid 
group. Triterpenoid is a chemical structure based on lanosterol, an important intermediate 
with biological and pharmacological effects such as inducing antitumor activity, via induction 
of apoptosis, and increasing levels of Bax protein. (Luis, et al. 2012). These compounds have 
showed cytotoxic effect on Meth-A (sarcoma) and on other tumor cells. (Sliva, 2004).  
Also, previous studies have shown that Ganodermanondiol inhibits the growth of cancer cells, 
specifically it showed cytotoxicity against HeLa and Meth-A tumoral cell lines (Río et al., 
2012).  
Cerevisterol is a polyoxygenated ergostanoid that showed cytotoxicity against different types 
of human cancer cells. A known Cerevisterol protein target is polymerase ɑ (Ferreira et al., 
2010). In this study, we hypothesized that Cerevisterol may also exert his anti tumoral activity 
by targeting Bcl-2. 
Ganoderic acids from Ganoderma Lucidum are characterized by their hydroxylation in the 
triterpene lactone structure which could be promising as natural agents for further study of 
invasive breast cancers (Roupas et al., 2012). These compounds showed cytotoxicity against 
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hepatoma cells in vitro (Sliva, 2004). Ganoderic acid X has the ability to inhibit 
topoisomerases, to produce apoptosis through degradation of chromosomal DNA, reduction 
of the antiapoptotic protein Bcl-xL, and disruption of the mitochondrial membrane. (Ríos et 
al., 2012). Again, our virtual screening showed that Ganoderic acid X may also produce his 
anti tumoral activity by inhibiting Bcl-2. Although the other Ganoderic acids screened 
presented lower estimated Bcl-2 inhibition activity, they may also act synergistically with 
Ganoderic acid X to promote even more potent Bcl-2 inhibition.  
Lucidenic lactone prevented not only the activity of calf DNA polymerase ɑ but also those of 
human immunodeficiency virus type 1 reverse transcriptase (Ferreira et al., 2010). In this 
study we add Bcl-2 as a probable new target for Lucidenic lactone. 
 Moreover, previous studies on our research group demonstrated that 48 h treatment of MCF-
7 cells (breast carcinoma) with Suillus collinitus methanolic extract caused a decrease in Bcl-
2, highlighting the antitumor potential of this mushroom species (Vaz et al., 2012). 
Despite the promising results in this virtual screening study and considering the mushroom 
LMW compounds anti-tumor bioactivity evidences presented above, the activity of the top 
ranked compounds against Bcl-2 must still be experimentally proven. There is still a 
reasonable degree of uncertainty in docking scoring predictions, and we must have presented 
that other steroids which were ranked lower in relation to the top four should also be 
considered as potential Bcl-2 inhibitor.  
 
3.3. Structural analysis of the top ranked steroids as Bcl-2 inhibitors 
In order to better understand the possible mechanism of action of the top ranked LMW 
compounds mushrooms as Bcl-2 inhibitors, a detailed analysis of the estimated docking 
conformation (pose) was performed. Analysis and visualization of the docking pose of the 4 
top ranked compounds into the active site of Bcl-2 was performed using Pymol software. This 
analysis focused on the predicted interaction bonds and the determination of the key amino 
acid residues that may interact with the LMW compounds. The docking pose of the 
compounds with Bcl-2 amino acid residues are presented in the Figure 8, with the residues 
involved in the Hydrogen bonds (H-bond) and van der Waals interactions presented in Table 
6. 
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Figure 8. Docked conformations of the top ranked LMW compounds against Bcl-2 structure. 
Compounds are presented as sticks models (cyan color). A: Ganodermanondiol (6j); B: Cerevisterol 
(6f); C: Ganoderic acid X (6o) and D: Lucidenic Lactone (6e). The Bcl-2 structure used was PDB: 
4LVT, and key amino acid residues are labeled and presented as sticks models (white color). The H-
bonds are colored red and the van der Waals interactions are shown in yellow color. Analysis and 
image preparation was performed using Pymol software. 
 
The first pose to be structurally analyzed was the top ranked Ganodermanondiol (Figure 8A). 
This steroid presents the characteristic 4 ring steroid hydrophobic skeleton punctuated by 2 
hydroxyl groups and 1 carbonyl group. The steroid skeleton was predicted to be located more 
to the inside of the Bcl-2 interaction site, forming 6 Van der Waals interactions between 
methyl (CH3) or methylene (CH2) groups and key amino acid residues (Figure 8A and Table 
6). The docking conformation is also predicted to be stabilized by 4 H-bonds between the 
hydroxyl groups (OH) or carbonyl group (C=O) and several key amino acid residues. The 
amino acid residues that form H-bonds are located on more exposed position of Bcl-2 
structure, as expected due to the hydrophilic nature of most of them. Overall, this analysis 
shows a structurally credible scenario, where the hydrophobic regions of Ganodermanondiol 
are located more to the hydrophobic interior of Bcl-2 interaction site, and the hydrophilic 
hydroxyl or carbonyl groups are located more in solvent exposed regions. All the individual 
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predicted interactions contribute to the low estimated binding energy for Ganodermanondiol 
and, as a general rule, the more the number of predicted interactions, the lower the estimated 
binding energy. 
Table 6. Predicted interactions of the top ranked LMW compounds as Bcl-2 inhibitors. 
*Results obtained using AD4; **Results obtained using Pymol  
 
Cerevisterol was the second top ranked LMW compound in our virtual screening study, and 
its docked conformation is presented in Figure 8B. Surprisingly, Cerevisterol was not 
predicted to perform any H-bond in the docked pose obtained. Still a total of 14 van der 
Compound 
codes 
Estimated ΔG 
average 
(Kcal/mol)* 
Molecular interactions** 
Compound 
Group 
Bcl-2 
residue 
Distance 
(Aᵒ) 
Compound 
Group 
Bcl-2 
residue 
Distance 
(A°) 
6j -8,45 
H-Bonds Van der Waals interactions 
OH Arg104 3,2 CH3 Arg104 3,5 
C=O Arg 143 2,8 CH2 Phe101 3,2 
C=O Asn140 3,2 CH2 Phe101 3,4 
OH Asp100 2,6 CH3 Val145 3,5 
   CH3 Gly142 3,0 
   CH3 Tyr105 3,6 
6f -8,43 
Van der Waals interactions 
OH Val153 2,8 CH2 Ala146 3,1 
OH Met112 3,2 CH2 Phe101 3,2 
OH Asp108 3,0 CH3 Phe101 3,6 
CH2 Phe105 3,6 CH2 Leu134 3,3 
CH2 Met112 3,5 CH2 Ala146 3,1 
CH3 Asn140 3,3 CH2 Asp108 3,4 
CH2 Gly142 3,4 CH2 Asp108 3,0 
6o -8,33 
H-Bonds Van der Waals interactions 
COOH Phe195 2,9 COOH Trp141 3,5 
COOH Tyr199 2 .8 OH Arg101 3.0 
   CH2 Tyr199 3.5 
   CH3 Ala97 2.9 
   CH3 Phe101 3.8 
   CH2 Gly142 2.7 
   
CH3 Gly142 3.1 
   CH2 Ala146 3.6 
 
 
 
   
CH2 Tyr105 2.8 
   COOH Phe101 2.8 
 
6e 
 
-8,30 
 
Van der Waals interactions 
OH Leu198 3,2 CH2 Arg104 3,1 
C=O Val145 3,3 CH2 Trp141 3,7 
OH Gly142 3,0 CH3 Phe195 3,8 
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Waals interactions (Table 6) were predicted, and these interactions, although weaker than H-
bonds, probably account for Cerevisterol predicted Bcl-2 inhibition ability. 
Ganoderic acid X best docked conformation was able to form 2 H-bonds between the 
carboxyl group and 2 key amino acid residues, Phe195 and Tyr199 (Figure 8C). The steroid 
skeleton of Ganoderic acid X was then stabilized by 10 van der Waals interactions. 
Finally, Lucidenic Lactone was last of the top ranked LMW compounds present in 
mushrooms, whose docked conformation was structurally analyzed (Figure 8D). Like 
Cerevisterol, Lucidenic Lactone was also not predicted to perform any H-bond. The docked 
conformation was only stabilized by a total of 6 van der Waals interactions. This small 
number of compound-Bcl-2 structure interaction probably accounts for the slightly lower 
binding energy obtained for Lucidenic Lactone. 
  
31 
 
4. CONCLUSION AND FUTURE PERSPECTIVES 
In this work, a comprehensible study was performed, in order to virtually screen a LMW 
database of 40 compounds, known to be present in mushrooms, against Bcl-2, a protein target 
that has been receiving much attention recently in the discovery of new anticancer drugs.  
A lot of attention has been given to the initial process of selecting the best virtual screening 
methodology. Using a cross-docking and re-docking approach, and testing two molecular 
docking softwares: AutoDock 4 and AutoDock Vina, a computational methodology was 
stablished, where the average estimated binding energy (∆G) and binding constant (Ki), 
obtained by AutoDock 4, were the selected parameters to score and rank the LMW 
compounds as potential Bcl-2 inhibitors. 
The selected virtual screening methodology was then applied to the 40 LMW compounds 
dataset. The results point to steroids as the compound class with the best docking scores, 
presenting the lowest ∆G and Ki values. Steroid compounds with best predicted results 
against Bcl-2 were: Ganodermanodiol, Cerevisterol, Ganoderic Acid X and Lucidenic 
Lactone; with estimated ∆G values between -8,45 and -8,23 Kcal/mol, and estimated Ki 
values between 645 and 935 nM. Also, a detailed docking conformation analysis of the 4 top 
ranked LMW compounds was performed, and shows a plausible three-dimensional 
interaction, with a large number of estimated molecular interactions between the top ranked 
steroids and Bcl-2 interaction site.  
This analysis provides evidence that steroids present in mushrooms may in fact be 
responsible, at least partially, for the antitumor and pro-apoptotic activities that has been 
discovered in a large number of mushroom species; and that the molecular mechanism of 
these activities may be through promoting Bcl-2 inhibition. Still, it´s important to stress that 
the reported studies were all performed using bioinformatic tools, and that further studies are 
needed to experimentally confirm the conclusions of this work. 
For future work several directions can be considered: 
- The use of molecular dynamic simulations to confirm the plausibility of the docking 
conformations obtained. 
- More Bcl-2 inhibitors, with known experimental Ki values, could be used in the 
methodology selection step, in order to turn the docking methodology even more robust and 
reliable. 
32 
 
- Considering the growing number of publications studying mushroom properties and 
composition, the 40 LMW compound dataset could be enlarged to encompass more 
compounds. Also it could be considered to go beyond mushrooms and include compounds 
present in relevant aromatic and medicinal plants. 
- More proteins from the Bcl-2 family are being considered as potential targets in the drug 
discovery process, namely Bcl-XL and Mcl-1, and could also be studied as potential target of 
the LMW compounds dataset. 
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